Aims and scope
Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.
Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.
Cancer Gene Therapy covers a range of subject areas, to read content across the scope of the journal view the journal's subjects page here.
12 issues a year
Our publishing models
Cancer Gene Therapy is a Transformative Journal (TJ). When research is accepted for publication, authors can choose to publish using either the traditional publishing route OR via immediate gold Open Access.
Cancer Gene Therapy is actively committed to becoming a fully Open Access journal. We will increase the number of articles we publish OA, with the eventual goal of becoming a fully Open Access journal. A journal that commits to this process is known as a Transformative Journal.
Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles) then you should select the gold OA route, and we will direct you to the compliant route where possible. For authors selecting the subscription publication route our standard licensing terms will need to be accepted including our self-archiving policies. Those standard licensing terms will supersede any other terms that the author or any third party may assert apply to any version of the manuscript.
Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.
The 2020 peer review performance metrics for Cancer Gene Therapy are shown below:
Average time to decision without external review - 5 days
Average time to decision following external review - 37 days
Average time from submission to acceptance - 128 days
Average time from acceptance to publication - 21 days
Article page views - 361,676
Altmetric mentions - 954
The 2020 journal metrics for Cancer Gene Therapy are as follows:
2-year Impact Factor*: 5.987
5-year Impact Factor*: 5.358
Immediacy index*: 1.755
Eigenfactor® score*: 0.00272
Article influence score*: 0.987
JCR Rank*: 34/140 Medicine, Research & Experimental; 66/242 Oncology; 21/159 Biotechnology & Applied Microbiology; 26/175 Genetics & Heredity
Journal Citation Score*: 1.26
Science Citation Index
Science Citation Index Expanded
Current Contents/Clinical Medicine
Current Contents/Life Sciences
Summon by ProQuest
EBSCO Discovery Service
EBSCO Academic Search
ISSN and eISSN
The international standard serial number (ISSN) for Cancer Gene Therapy is 0929-1903, and the electronic international standard serial number (eISSN) is 1476-5500.
Cancer Gene Therapy now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.